HLA-targeted sequencing reveals the pathogenic role of HLA-B15:02/HLA-B13:01 in albendazole-induced liver failure: a case report and a review of the literature

Drug-induced liver injury (DILI) is one of the serious adverse drug reactions (ADRs), which belongs to immune-mediated adverse drug reactions (IM-ADRs). As an essential health drug, albendazole has rarely been reported to cause serious liver damage. A young man in his 30 s developed severe jaundice,...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2023-11, Vol.14
Main Authors: Liao, Jin-Mao, Zhan, Yan, Zhang, Zheng, Cui, Jia-Jia, Yin, Ji-Ye
Format: Article
Language:English
Subjects:
DILI
genetic susceptibility
HLA polymorphism
IM-ADRs
liver injury
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug-induced liver injury (DILI) is one of the serious adverse drug reactions (ADRs), which belongs to immune-mediated adverse drug reactions (IM-ADRs). As an essential health drug, albendazole has rarely been reported to cause serious liver damage. A young man in his 30 s developed severe jaundice, abnormal transaminases, and poor blood coagulation mechanism after taking albendazole, and eventually developed into severe liver failure. The patient was found heterozygous of HLA-B*15:02 and HLA-B*13:01 through HLA-targeted sequencing, which may have a pathogenic role in the disease. This case report summarizes his presentation, treatment, and prognosis. A useful summary of the diagnosis and associated genetic variant information is provided.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2023.1288068